Electro-Optical Sciences, Inc. (MELA) Announces Positive Top-Line Results from MelaFind(R) Pivotal Trial
Early this morning, Electro-Optical Sciences, Inc. announced positive top-line results of its pivotal trial of MelaFind, a non-invasive, point-of-care instrument to assist in the early detection of melanoma, the deadliest form of skin cancer. The blinded study was conducted at seven centers across the US and included 1,831 pigmented skin lesions from 1,383 patients, making it the largest prospective study ever conducted in melanoma detection. The company is currently completing its Pre-Market Approval (PMA) application and anticipates filing it with the US Food and Drug Administration (FDA) in the near future. "MelaFind appears to be an excellent tool to help…